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The	future	of	UK	supply	chains	in	a	disrupted	world:
Brexit	and	Covid-19
Brexit	and	Covid-19	are	typically	considered	distinct	events.	However,	these	events	have	one	thing	in	common:
they	have	significantly	disrupted	the	supply	chains	of	UK	firms.	Since	the	1980s,	many	UK	companies	have	set	up
centralised	manufacturing	facilities	in	low-wage	economies	where	finished	goods	are	assembled	cheaply	and
shipped	to	higher	income	markets.	Brexit	and	Covid-19	have	delivered	a	one-two	punch	to	this	model;	forcing
companies	to	reconsider	the	short-term	benefits	and	long-term	sustainability	of	low-cost,	centralised,	production.
A	key	difference	between	Brexit	and	the	Covid-19	pandemic	is	that	companies	had	time	to	plan	for	Brexit.	While
many	companies	viewed	Brexit	as	a	high-probability,	high-impact	event,	the	chance	of	a	global	pandemic	was	seen
as	low-probability,	high-impact	–	if	a	pandemic	was	considered	at	all.	Both	events	had	the	potential	to	affect	every
aspect	of	the	supply	chain	from	access	to	labour,	delays	at	ports,	increased	distribution	costs	and	inaccessibility	of
raw	materials	and	subcomponents.
An	examination	of	the	pharmaceutical	industry	highlights	the	impact	these	events	have	had	on	global	supply
chains.	When	the	pro-Brexit	vote	was	announced	in	June	2016,	several	multi-national	pharmaceutical	firms	adopted
a	worst-case	scenario	planning	approach.	The	key	assumption	made	by	these	companies	was	that	the	UK	would
leave	the	EU	without	a	deal	and	trade	would	revert	to	WTO	terms.	By	planning	based	on	worst-case	assumptions,
these	companies	did	not	see	Brexit	as	a	strategic	supply	chain	risk,	but	as	an	operational	issue	that	could	be
managed	on	a	day-to-day	basis.	Any	other	outcome	than	a	no-deal	was	viewed	as	a	positive	result	for	these	firms.
Multi-national	companies	were	in	the	fortunate	position	to	have	the	millions	of	pounds	needed	to	invest	in	new
supply	chain	assets	in	Europe	and	establish	new	qualified	personnel	and	quality	control	checks	on	the	continent.
With	the	prompting	of	the	UK	government,	large	pharma	firms	built	six	weeks	of	buffer	inventory	in	the	supply	chain.
Indeed,	one	reason	why	the	pharmaceutical	industry	has	been	able	to	avoid	out-of-stocks	on	many	product	lines
during	the	pandemic	is	because	they	were	holding	six	weeks	of	inventory	in	the	event	of	a	no-deal	Brexit.	In
contrast,	many	small	and	medium	enterprises	(SMEs)	adopted	a	‘wait-and-see’	approach	to	Brexit	because	they	did
not	have	sufficient	financial	resources	to	make	supply	chain	investments	while	the	future	EU-UK	trading	relationship
remained	ambiguous.	After	almost	four	years,	SMEs	are	still	uncertain	about	Britain’s	future	trading	relationship
with	Europe	and	unsure	how	to	absorb	the	potential	costs	that	may	come	from	increased	tariff	and	non-tariff
barriers.
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Covid-19	has	significantly	amplified	the	supply	chain	uncertainty	created	by	Brexit.	The	pandemic	has	led	to	rolling
production	stoppages	across	the	globe,	starting	in	China	and	moving	to	Europe,	the	USA	and	now	India	and	South
America.	At	the	outset,	governments	in	India	and	Europe	restricted	exports	of	medicines	and	medical	equipment	to
ensure	there	was	sufficient	volume	for	their	own	populations.	Delays	occurred	at	border	crossings	and	transport
capacity	was	reduced	due	to	labour	shortages	and	cuts	in	passenger	haulage.	The	uncertainty	of	the	future	EU-UK
trading	relationship,	coupled	with	the	uncertainty	of	finding	a	vaccine	for	Covid-19,	means	UK	companies	now	need
to	prioritise	resilience	and	responsiveness	over	cost	and	efficiency.
In	the	first	instance,	companies	need	to	spread	risk	geographically	by	sourcing	from	a	dispersed	range	of	countries
and	regions.	Decisions	on	where	to	source	products	will	be	largely	dictated	by	the	trade	deals	that	Britain	strikes
with	countries	after	leaving	the	EU.	Dual	and	multiple	sourcing	agreements	will	be	required	for	critical	raw	materials
and	components.	Companies	will	need	to	map	the	entirety	of	their	supply	chains,	up	to	and	including	raw	materials,
to	create	end-to-end	visibility	and	identify	bottleneck	suppliers.	Bottlenecks	emerge	when	only	one	or	two	suppliers
are	available	in	the	market	to	provide	materials.	Contingency	plans	will	be	required	to	quickly	move	production
volumes	away	from	bottleneck	suppliers	to	other	locations	when	a	future	crisis	occurs.	Companies	will	also	need
new	key	performance	indicators	that	measure	supply	chain	disruptions.	As	part	of	an	on-time	and	in-full	(OTIF)
delivery	metric,	companies	can	track	the	percentage	of	delays/shortages	from	suppliers	due	to	manufacturing
disruptions,	natural	disruptions	(natural	disasters,	weather,	pandemics)	and	man-made	disruptions	(new	regulatory
regimes,	war,	border	closures).	Companies	can	also	track	a	supplier’s	overall	time	to	recover	(OTTR),	a	measure	of
the	time	elapsed	until	a	supplier	reaches	100%	production	output	following	a	supply	chain	disruption.
Another	important	factor	in	a	post-Brexit,	and	hopefully	post-pandemic,	world	will	be	a	transition	from	a	centralised
to	a	decentralised	manufacturing	model.	Automotive	and	apparel	companies	have	already	adopted	regionalised
manufacturing	models	where	production	facilities	are	located	in	‘near-shored’	countries	(Mexico,	Poland,
Bangladesh)	and	products	are	shipped	to	larger	markets	such	as	China,	Germany	and	the	USA.	Covid-19	and
geopolitical	disruptions	such	as	the	US-China	trade	war	and	Brexit	will	accelerate	this	trend.
Following	on	from	the	regionalisation	trend	will	be	the	increased	distribution	of	manufacturing,	with	products	made
locally	–	closer	to	customers.	Establishing	parallel	supply	chains	will	accelerate	the	localisation	of	production.
Drawing	on	our	pharmaceutical	example,	a	parallel	supply	chain	would	mean	having	20-30%	of	pharmaceutical
manufacturing	located	in	the	UK,	including	active	pharmaceutical	ingredients	(APIs),	excipients	and	packaging.	The
remaining	70-80%	would	remain	overseas	using	the	centralised,	low-cost	model.	When	a	crisis	such	as	a
geopolitical	dispute	or	pandemic	hit,	production	volumes	would	be	transitioned	to	the	UK.		If	a	company	expected	it
to	take	3	to	4	months	to	ramp	up	UK	production,	then	3	to	4	months	of	finished	goods	inventory	would	be	held	in
the	UK.	The	parallel	supply	chain	approach	is	particularly	relevant	for	companies	that	provide	life-saving	products
(drugs,	PPE,	ventilators).	Pharma	companies	could	begin	by	identifying	critical	drugs	that	treat	the	symptoms	of
coronaviruses,	and	locate	a	proportion	of	manufacturing	capacity	in	the	UK.	The	parallel	supply	chain	model	is	also
applicable	to	industries	such	as	aerospace	and	automotive,	which	have	long	and	complex	supply	chains.	Parallel
supply	chains	will	require	advanced	manufacturing	technologies	such	as	additive	and	continuous	manufacturing	to
counteract	the	high	labour	costs	associated	with	UK	based	manufacturing,	Localised	supply	chains	have	the	added
benefit	of	reducing	inventory-carrying	costs	by	shortening	supply	chains	and	improving	responsiveness	to	demand.
While	multinational	firms	adopted	a	worst-case	scenario	planning	approach	to	Brexit,	the	same	approach	has	yet	to
be	seen	with	Covid-19.	If	multinational	companies	believe	that	a	pandemic	is	likely	to	happen	again,	or	that	a
second/third	wave	of	Covid-19	will	shut	down	global	production,	then	a	logical	conclusion	would	be	to	establish	a
percentage	of	manufacturing	in	the	UK.	Indeed,	the	combined	uncertainty	of	Brexit	and	Covid-19	mean	that
companies	can	no	longer	‘wait-and-see’.	Today’s	uncertain	world	necessitates	new	supply	chain	models	that
prioritise	resilience	and	responsiveness	over	low-cost,	centralised	production.
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